We developed a novel BCMA‐targeted CAR T cells therapy, and now report results from our phase I clinical trial evaluating anti‐BCMA CAR T Cell in R/R MM patients and primary PCL, which, to our knowledge, represents the first report involving CAR T cell treatment for primary PCL. Here, TNFRSF17 is linked to plasma cell leukemia.